Epigenetic silencing of MGMT by gene promoter methylation compromises DNA repair and is associated with longer survival in patients receiving alkylating agent chemotherapy: Hegi et al.[14] reported that in a cohort of 206 glioblastoma patients, MGMT was silenced in 45% GBM cases at diagnosis and confered longer survival in patients receiving TMZ. The gene discussed is MGMT; the disease is glioblastoma.